Stifel analyst Paul Matteis reiterated a Buy rating on Dyne Therapeutics (NASDAQ: DYN), following the company's announcement of DYNE-101's CTA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE